Ask AI
ProCE Banner Activity

Key Updates in Lung Cancers From the ELCC 2024 Annual Meeting

Conference Coverage
Clinical Thought

Lung cancer experts highlight key studies from the 2024 European Lung Cancer Congress. CCO’s Independent Conference Coverage has the information you need to understand and integrate the latest data into your management of patients with NSCLC and SCLC.

Released: May 03, 2024

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc

Faculty Disclosure

Primary Author

Luis Paz-Ares, MD, PhD

Chair of the Department of Medical Oncology
Hospital Universitario 12 de Octubre
Professor of Medicine at Universidad Computense de Madrid
Co-Director at the Spanish National Cancer Research Center (CNIO) and Head of the Lung Cancer Unit
Madrid, Spain

Luis Paz-Ares, MD, PhD: other/grant: AstraZeneca, BMS, MSD, Pfizer; consultant/advisor/speaker: Amgen, AstraZeneca, Bayer, BMS, Daichii Sankyo, GSK, Janssen, Lilly, Merck, Mirati, MSD, Novartis, Pfizer, Pharmamar, Roche, Sanofi, Servier, Takeda; executive role: Altum Sequencing, Stab Therapeutics.

 

 

 

Zofia Piotrowska, MD, MHS

Associate Professor of Medicine, Harvard Medical School
Clinical Co-Director, MGB Thoracic Medical Oncology Program
Mass General Brigham Cancer Institute
Boston, Massachusetts

Zofia Piotrowska, MD, MHS: consultant/advisor/speaker: AbbVie, AstraZeneca, Bayer, Blossom Hill Therapeutics, Boehringer Ingelheim, Daiichi Sankyo, Genmab, Gilead, Janssen, Lilly, Natera, Regeneron, Revolution Medicines, Summit, Taiho, Takeda, Tubulis; researcher: AbbVie, AstraZeneca, Blossom Hill Therapeutics, Blueprint Medicines, Cullinan Oncology, Daiichi Sankyo, Janssen, Novartis, Nuvalent, Spectrum, Systimmune, Takeda, Tesaro/GSK.